Acta Med. 2017, 60: 167-170
https://doi.org/10.14712/18059694.2018.15
SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
References
1. JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016, 65(8): 1096–1108.
<https://doi.org/10.1016/j.metabol.2016.01.001>
<PubMed>
2. S, Blau J, Rother, K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J. Clin. Endocrinol Metab 2015; 100(8): 2849–2852.
<https://doi.org/10.1210/jc.2015-1884>
<PubMed>
3. G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 2016; 39(11): 2036–2041.
<https://doi.org/10.2337/dc15-2688>
<PubMed>
4. E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65: 1190–1195.
<https://doi.org/10.2337/db15-1356>
5. E, Muscelli E, Frascerra S, et al. Metabolic response to sodium- glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124(2): 499–508.
<https://doi.org/10.1172/JCI72227>
<PubMed>
6. Kamei S, Iwamoto M, Kameyama M, et al. Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2018, Article ID 6470137, 6 pages.
7. Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, et al. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE 2016; 11(1): e0146337.
<https://doi.org/10.1371/journal.pone.0146337>
<PubMed>
8. C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE 2016; 11(3): e0151511.
<https://doi.org/10.1371/journal.pone.0151511>
<PubMed>
9. S, Katsuno K, Isaji M, et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol 2015; 5(3): 190–198.
<https://doi.org/10.1016/j.jceh.2015.02.005>
<PubMed>
10. A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715(1–3): 246–255.
<https://doi.org/10.1016/j.ejphar.2013.05.014>
11. Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 2015; 754: 19–24.
<https://doi.org/10.1016/j.ejphar.2015.02.009>
12. S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
<https://doi.org/10.1186/s13098-015-0102-8>
<PubMed>
13. W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE 2017; 12(6): e0179960.
<https://doi.org/10.1371/journal.pone.0179960>
<PubMed>
14. T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 2016; 8: 45.
<https://doi.org/10.1186/s13098-016-0169-x>
<PubMed>
15. K, Shirakami Y, Maruta A, et al. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine- induced liver tumorigenesis in obese and diabetic mice. Oncotarget 2017; 8(35): 58353–58363.
<https://doi.org/10.18632/oncotarget.16874>
<PubMed>
16. H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with non-alcoholic steatohepatitis associated with type 2 diabetes mellitus: A prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 2017; 87: 13–19.
<https://doi.org/10.1016/j.curtheres.2017.07.002>
<PubMed>
17. D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care 2017; 40(10): 1364–1372.
<https://doi.org/10.2337/dc17-0518>
18. LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42(1): 25–32.
<https://doi.org/10.1016/j.diabet.2015.10.003>
19. T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig 2016; 36(4): 313–319.
